Plasma clofibric acid (CPIB) levels induced by three marketed compounds releasing clofibric acid, in volunteers.
The very low plasma clofibric acid levels achieved in normolipemic volunteers during 96 h by a single dose of alufibrate (basic aluminum salt of clofibric acid) as 4 x 360 mg tablets, have been confirmed. With a crossover study in healthy volunteers receiving therapeutic doses of clofibrate as 2x500 mg capsules, clofibride as 2x450 mg capsules, twice daily for ten days, the plasma clofibric acid concentrations were already found in the therapeutic range after two days and remained above 80 mug/ml at the tenth day. On the other hand, the plasma clofibric acid concentrations measured during a ten-day administration of alufibrate as 2x360 mg tablets twice daily, were regularly found to be much lower at each time; they did not reach levels exceeding 60 mug/ml.
D000328:Adult; D000535:Aluminum / Q000097:blood; D001682:Biological Availability; D002994:Clofibrate / Q000031:analogs & derivatives* / Q000097:blood; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D013997:Time Factors
D000535:Aluminum; D002994:Clofibrate